Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer

被引：123

作者：

Roti, Giovanni ^{[1
,3
]}

Carlton, Anne ^{[1
,3
]}

Ross, Kenneth N. ^{[4
]}

Markstein, Michele ^{[5
]}

Pajcini, Kostandin ^{[6
,7
]}

Su, Angela H. ^{[1
,3
]}

Perrimon, Norbert ^{[8
,11
]}

Pear, Warren S. ^{[6
,7
]}

Kung, Andrew L. ^{[12
]}

Blacklow, Stephen C. ^{[2
,9
]}

Aster, Jon C. ^{[10
]}

Stegmaier, Kimberly ^{[1
,3
,4
]}

机构：

[1] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA

[2] Dana Farber Canc Inst, Canc Biol Program, Boston, MA 02215 USA

[3] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA

[4] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02142 USA

[5] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA

[6] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA

[7] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA

[8] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA

[9] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA

[10] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA

[11] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA

[12] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA

来源：

CANCER CELL | 2013年 / 23卷 / 03期

基金：

美国国家卫生研究院;

关键词：

SQUAMOUS-CELL TUMORS; C-MYC; MUTATIONS; GENE; LEUKEMIA; ACTIVATION; PRESENILIN; EXPRESSION; RECEPTOR; ATP2A2;

D O I：

10.1016/j.ccr.2013.01.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Notch1 is a rational therapeutic target in several human cancers, but as a transcriptional regulator, it poses a drug discovery challenge. To identify Notch1 modulators, we performed two cell-based, high-throughput screens for small-molecule inhibitors and cDNA enhancers of a NOTCH1 allele bearing a leukemia-associated mutation. Sarco/endoplasmic reticulum calcium ATPase (SERCA) channels emerged at the intersection of these complementary screens. SERCA inhibition preferentially impairs the maturation and activity of mutated Notch1 receptors and induces a G(0)/G(1) arrest in NOTCH1-mutated human leukemia cells. A small-molecule SERCA inhibitor has on-target activity in two mouse models of human leukemia and interferes with Notch signaling in Drosophila. These studies "credential" SERCA as a therapeutic target in cancers associated with NOTCH1 mutations.

引用

页码：390 / 405

页数：16

共 50 条

[21] Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative
Roti, Giovanni
Qi, Jun
Su, Angela
Varca, Antony
Aster, Jon C.
Bradner, James E.
Stegmaier, Kimberly
BLOOD, 2014, 124 (21)
[22] Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors
Lu, Xiaojing
Pang, Yuzhi
Cao, Hui
Liu, Xiaoxiao
Tu, Lin
Shen, Yanying
Jia, Xiaona
Lee, Jen-Chieh
Wang, Yuexiang
CANCER RESEARCH, 2021, 81 (09) : 2481 - 2494
[23] Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma
Veo, Bethany
Danis, Etienne
Pierce, Angela
Sola, Ismail
Wang, Dong
Foreman, Nicholas K.
Jin, Jian
Ma, Anqi
Serkova, Natalie
Venkataraman, Sujatha
Vibhakar, Rajeev
JCI INSIGHT, 2019, 4 (01)
[24] SELECTIVE BLOCKADE OF ONCOGENIC NOTCH1 WITH THE NEW SERCA INHIBITOR CAD204520
Marchesini, M.
Gherli, A.
Montanaro, A.
Sorrentino, C.
Pagliaro, L.
Rompietti, C.
Rizzi, F.
Stilli, D.
Winther, A. M. Lund
La Starza, R.
Mecucci, C.
Sportoletti, P.
Bublitz, M.
Brown, W. Dalby
Roti, G.
HAEMATOLOGICA, 2020, 105 : S46 - S47
[25] Aberrant Expression of Notch1 in Cervical Cancer
Li Sun1 Qimin Zhan2 Wenhua Zhang1 Yongmei Song2 Tong Tong2 1 Department of Gynecological Oncology
Chinese Journal of Clinical Oncology, 2007, (01) : 38 - 41
[26] NOTCH1 as a prognostic Factor in Breast Cancer
Engel, J.
Kaufhold, S.
Kantelhardt, J. E.
Thomssen, C.
Vetter, M.
GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : E22 - E22
[27] NOTCH signaling as a novel cancer therapeutic target
Miele, L.
Miao, H.
Nickoloff, B. J.
CURRENT CANCER DRUG TARGETS, 2006, 6 (04) : 313 - 323
[28] Drug and siRNA screens identify ROCK2 as a therapeutic target for ciliopathies
Claire E. L. Smith
Andrew J. Streets
Alice V. R. Lake
Subaashini Natarajan
Sunayna K. Best
Katarzyna Szymanska
Magdalena Karwatka
Thomas Stevenson
Rachel Trowbridge
Gary Grant
Sushma N. Grellscheid
Richard Foster
Ciaran G. Morrison
Georgia Mavria
Jacquelyn Bond
Albert C. M. Ong
Colin A. Johnson
Communications Medicine, 5 (1):
[29] Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
Silkenstedt, Elisabeth
Arenas, Fabian
Colom-Sanmarti, Berta
Xargay-Torrent, Silvia
Higashi, Morihiro
Giro, Ariadna
Rodriguez, Vanina
Fuentes, Patricia
Aulitzky, Walter E.
van der Kuip, Heiko
Bea, Silvia
Toribio, Maria L.
Campo, Elias
Lopez-Guerra, Monica
Colomer, Dolors
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
[30] Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
Elisabeth Silkenstedt
Fabian Arenas
Berta Colom-Sanmartí
Sílvia Xargay-Torrent
Morihiro Higashi
Ariadna Giró
Vanina Rodriguez
Patricia Fuentes
Walter E. Aulitzky
Heiko van der Kuip
Sílvia Beà
Maria L. Toribio
Elias Campo
Mònica López-Guerra
Dolors Colomer
Journal of Experimental & Clinical Cancer Research, 38

← 1 2 3 4 5 →